WO2009014216A1 - Ｃ型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体およびその用途 - Google Patents

Ｃ型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体およびその用途 Download PDF

Info

Publication number
WO2009014216A1
WO2009014216A1 PCT/JP2008/063424 JP2008063424W WO2009014216A1 WO 2009014216 A1 WO2009014216 A1 WO 2009014216A1 JP 2008063424 W JP2008063424 W JP 2008063424W WO 2009014216 A1 WO2009014216 A1 WO 2009014216A1
Authority
WO
WIPO (PCT)
Prior art keywords
coding sequence
protein coding
hcv
hepatitis
virus
Prior art date
Application number
PCT/JP2008/063424
Other languages
English (en)
French (fr)
Inventor
Takaji Wakita
Tetsuro Suzuki
Kenichi Morikawa
Noriaki Omi
Noriko Nakamura
Daisuke Akazawa
Original Assignee
Japan As Represented By Director-General Of National Institute Of Infectious Diseases
Toray Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan As Represented By Director-General Of National Institute Of Infectious Diseases, Toray Industries, Inc. filed Critical Japan As Represented By Director-General Of National Institute Of Infectious Diseases
Priority to JP2009524526A priority Critical patent/JPWO2009014216A1/ja
Priority to EP08791668A priority patent/EP2177535A4/en
Priority to CN200880108581A priority patent/CN101809033A/zh
Priority to US12/670,383 priority patent/US20100291545A1/en
Priority to CA2694397A priority patent/CA2694397A1/en
Priority to AU2008280057A priority patent/AU2008280057A1/en
Publication of WO2009014216A1 publication Critical patent/WO2009014216A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

　本発明は、Ｃ型肝炎ウイルス（HCV）の感染を阻害する抗体を提供することを目的としている。上記目的を達成するために、本発明は、下記の（i）と（ii）とが連結したＣ型肝炎ウイルス（HCV）ゲノムから得られるＣ型肝炎ウイルス（HCV）粒子を抗原として認識し、Ｃ型肝炎ウイルス（HCV）に対して感染阻害活性を有する抗体を提供する。 　（i）（ａ）Ｃ型肝炎ウイルス（HCV）のJFH-1株の5’非翻訳領域、coreタンパク質コード配列、E1タンパク質コード配列、E2タンパク質コード配列およびp7タンパク質コード配列、または（ｂ）Ｃ型肝炎ウイルス（HCV）のJ6CF株の5’非翻訳領域、coreタンパク質コード配列、E1タンパク質コード配列、E2タンパク質コード配列およびp7タンパク質コード配列 　（ii）JFH-1株のNS2タンパク質コード配列、NS3タンパク質コード配列、NS4Aタンパク質コード配列、NS4Bタンパク質コード配列、NS5Aタンパク質コード配列、NS5Bタンパク質コード配列および3’非翻訳領域
PCT/JP2008/063424 2007-07-25 2008-07-25 Ｃ型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体およびその用途 WO2009014216A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2009524526A JPWO2009014216A1 (ja) 2007-07-25 2008-07-25 Ｃ型肝炎ウイルス（ｈｃｖ）に対して感染阻害活性を有する抗体およびその用途
EP08791668A EP2177535A4 (en) 2007-07-25 2008-07-25 ANTIBODIES HAVING INHIBITORY ACTIVITY ON HEPATITIS C VIRUS INFECTION (HCV) AND USE THEREOF
CN200880108581A CN101809033A (zh) 2007-07-25 2008-07-25 对丙型肝炎病毒(hcv)感染具有抑制活性的抗体和其用途
US12/670,383 US20100291545A1 (en) 2007-07-25 2008-07-25 Antibody having inhibitory activity on infection with hepatitis c virus (hcv) and use thereof
CA2694397A CA2694397A1 (en) 2007-07-25 2008-07-25 Antibody having inhibitory activity on infection with hepatitis c virus (hcv) and use thereof
AU2008280057A AU2008280057A1 (en) 2007-07-25 2008-07-25 Antibody having inhibitory activity on infection with hepatitis C virus (HCV), and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-193413 2007-07-25
JP2007193413 2007-07-25

Publications (1)

Publication Number Publication Date
WO2009014216A1 true WO2009014216A1 (ja) 2009-01-29

Family

ID=40281462

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/063424 WO2009014216A1 (ja) 2007-07-25 2008-07-25 Ｃ型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体およびその用途

Country Status (7)

Country Link
US (1) US20100291545A1 (ja)
EP (1) EP2177535A4 (ja)
JP (1) JPWO2009014216A1 (ja)
CN (1) CN101809033A (ja)
AU (1) AU2008280057A1 (ja)
CA (1) CA2694397A1 (ja)
WO (1) WO2009014216A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011052735A1 (ja) * 2009-10-30 2011-05-05 東レ株式会社 C型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体及びその用途
JPWO2012133735A1 (ja) * 2011-03-31 2014-07-28 国立感染症研究所長 遺伝子型１ｂのＣ型肝炎ウイルスゲノム由来の核酸を含む核酸構築物、及び該核酸構築物が導入されたＣ型肝炎ウイルスゲノム複製細胞、並びに感染性Ｃ型肝炎ウイルス粒子の製造方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8618275B2 (en) * 2007-05-18 2013-12-31 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 5A
US8569472B2 (en) * 2007-12-20 2013-10-29 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 6A
US8506969B2 (en) 2008-08-15 2013-08-13 Hvidovre Hospital Efficient cell culture system for hepatitis C virus genotype 7a
WO2010017818A1 (en) 2008-08-15 2010-02-18 Hvidovre Hospital Efficient cell culture system for hepatitis c virus genotype 2b
WO2010037403A1 (en) 2008-10-03 2010-04-08 Hvidovre Hospital Hepatitis c virus expressing reporter tagged ns5a protein
ES2694203T3 (es) 2012-03-08 2018-12-19 Ludwig Institute For Cancer Research Limited Anticuerpos específicos del Tgf-1 y métodos y usos de los mismos
BR112014022200A2 (pt) 2012-03-08 2019-09-24 Selig Sealing Products Inc membro de vedação de recipiente com compodnente de segurança protegido e aba de remoção
CN103642792B (zh) * 2013-12-25 2016-03-30 武汉大学 一种抗丙肝病毒的中和性单克隆抗体的制备及其应用
CN106661568A (zh) * 2014-03-20 2017-05-10 日本国立感染症研究所 对丙型肝炎病毒具有感染抑制活性的抗体
WO2017223283A1 (en) * 2016-06-22 2017-12-28 Icahn School Of Medicine At Mount Sinai Hcv core and minicore binding molecules
EP3530282A1 (en) * 2018-02-27 2019-08-28 Diaccurate Therapeutic methods
CN112898420A (zh) * 2021-02-09 2021-06-04 天津佰恒生物科技有限公司 人-人嵌合型抗病毒IgG抗体阳性质控品的制备方法及其应用

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125023A1 (en) 1983-04-08 1984-11-14 Genentech, Inc. Recombinant immunoglobulin preparations, methods for their preparation, DNA sequences, expression vectors and recombinant host cells therefor
JPS63276490A (ja) 1987-05-08 1988-11-14 Toray Ind Inc 組換え体ｄｎａおよび形質転換体
JPH06505389A (ja) 1991-01-31 1994-06-23 アボット・ラボラトリーズ 推定ｈｃｖエンベロープ領域に対するモノクローナル抗体およびその使用方法
JP2004000179A (ja) 2002-03-29 2004-01-08 Toray Ind Inc Ｃ型慢性肝炎、肝硬変、肝癌病態を呈するモデル動物及びその作製方法
JP2004500366A (ja) 1999-12-01 2004-01-08 カイロン　コーポレイション Ｃ型肝炎ウイルス（ｈｃｖ）について特異的な抗体を誘発すること
WO2004104198A1 (ja) 2003-05-26 2004-12-02 Toray Industries, Inc. 遺伝子型2aのC型肝炎ウイルス（HCV）ゲノム由来の核酸を含む核酸構築物、及び該核酸構築物を導入した細胞
WO2005080575A1 (ja) 2004-02-20 2005-09-01 Tokyo Metropolitan Organization For Medical Research ヒトｃ型肝炎ウイルスの全長ゲノムを含む核酸構築物及び該核酸構築物を導入した組換え全長ウイルスゲノム複製細胞、並びにｃ型肝炎ウイルス粒子の作製方法
JP2005531286A (ja) 2002-01-30 2005-10-20 ロベルト・ブリオニ ＨＣＶＥ２グリコプロテインに対して向けられ、ｉｎｖｉｔｒｏ中和活性を有するヒトモノクローナル抗体Ｆａｂ断片
JP2006504645A (ja) 2002-07-02 2006-02-09 ボード オブ トラスティーズ オブ リーランド スタンフォード ジュニア ユニバーシティ 立体構造及び直鎖状エピトープに対する抗体を用いたｈｃｖ感染の予防及び治療
WO2006022422A1 (ja) 2004-08-24 2006-03-02 Tokyo Metropolitan Organization For Medical Research 自律複製能を有する改変されたヒトｃ型肝炎ウイルスゲノムrna
WO2006096459A2 (en) 2005-03-04 2006-09-14 The Rockefeller University Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
WO2006100449A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
JP2007193413A (ja) 2006-01-17 2007-08-02 Nec Personal Products Co Ltd データ記憶装置および暗号鍵保存方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150990A1 (en) * 1992-02-28 2002-10-17 Ian Pike Hepatitis C virus peptides
US20060188511A1 (en) * 1998-11-05 2006-08-24 Foung Steven K Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
WO2007143701A2 (en) * 2006-06-06 2007-12-13 Progenics Pharmaceuticals, Inc. Monoclonal antibodies that potently neutralize hepatitis c virus (hcv) of diverse genotypes

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125023A1 (en) 1983-04-08 1984-11-14 Genentech, Inc. Recombinant immunoglobulin preparations, methods for their preparation, DNA sequences, expression vectors and recombinant host cells therefor
JPS63276490A (ja) 1987-05-08 1988-11-14 Toray Ind Inc 組換え体ｄｎａおよび形質転換体
JPH06505389A (ja) 1991-01-31 1994-06-23 アボット・ラボラトリーズ 推定ｈｃｖエンベロープ領域に対するモノクローナル抗体およびその使用方法
JP2004500366A (ja) 1999-12-01 2004-01-08 カイロン　コーポレイション Ｃ型肝炎ウイルス（ｈｃｖ）について特異的な抗体を誘発すること
JP2005531286A (ja) 2002-01-30 2005-10-20 ロベルト・ブリオニ ＨＣＶＥ２グリコプロテインに対して向けられ、ｉｎｖｉｔｒｏ中和活性を有するヒトモノクローナル抗体Ｆａｂ断片
JP2004000179A (ja) 2002-03-29 2004-01-08 Toray Ind Inc Ｃ型慢性肝炎、肝硬変、肝癌病態を呈するモデル動物及びその作製方法
JP2006504645A (ja) 2002-07-02 2006-02-09 ボード オブ トラスティーズ オブ リーランド スタンフォード ジュニア ユニバーシティ 立体構造及び直鎖状エピトープに対する抗体を用いたｈｃｖ感染の予防及び治療
WO2004104198A1 (ja) 2003-05-26 2004-12-02 Toray Industries, Inc. 遺伝子型2aのC型肝炎ウイルス（HCV）ゲノム由来の核酸を含む核酸構築物、及び該核酸構築物を導入した細胞
WO2005080575A1 (ja) 2004-02-20 2005-09-01 Tokyo Metropolitan Organization For Medical Research ヒトｃ型肝炎ウイルスの全長ゲノムを含む核酸構築物及び該核酸構築物を導入した組換え全長ウイルスゲノム複製細胞、並びにｃ型肝炎ウイルス粒子の作製方法
WO2006022422A1 (ja) 2004-08-24 2006-03-02 Tokyo Metropolitan Organization For Medical Research 自律複製能を有する改変されたヒトｃ型肝炎ウイルスゲノムrna
WO2006096459A2 (en) 2005-03-04 2006-09-14 The Rockefeller University Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
WO2006100449A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
JP2007193413A (ja) 2006-01-17 2007-08-02 Nec Personal Products Co Ltd データ記憶装置および暗号鍵保存方法

Non-Patent Citations (35)

* Cited by examiner, † Cited by third party
Title
"Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
"Cellular Immunology", 1980, W.H. FREEMAN AND COMPANY, article "Selected Methods"
"Remington's Pharmaceutical Science", MARK PUBLISHING COMPANY
APPAIAHGARI ET AL., VACCINE, vol. 22, 2004, pages 3669 - 3675
BARTOSCH B. ET AL.: "In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes", PROC. NATL. ACAD. SCI. USA, vol. 100, no. 24, 2003, pages 14199 - 14204, XP003001855 *
BOOTH J.C.L. ET AL.: "Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients", HEPATOLOGY, vol. 27, no. 1, 1998, pages 223 - 227, XP008129434 *
BURIONI ET AL., J. VIROL., vol. 76, 2002, pages 11775 - 11779
CHOO ET AL., SCIENCE, vol. 244, 1989, pages 359 - 362
COCQUEREL, L. ET AL., ET AL., J. VIROL., vol. 74, 2000, pages 3623 - 3633
COCQUEREL, L. ET AL., J. VIROL., vol. 74, 2000, pages 3623 - 3633
HADLOCK ET AL., J. VIROL., vol. 74, 2000, pages 10407 - 10416
KATO, T. ET AL., GASTROENTEROLOGY, vol. 125, 2003, pages 1808 - 1817
LINDENBACH, B.D. ET AL., SCIENCE, vol. 309, 2005, pages 623 - 626
MATSUURA ET AL., J. VIROL., vol. 66, 1992, pages 1425 - 1431 1
MORADPOUR ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 246, 1998, pages 920 - 924
NAT MED., vol. 11, 2005, pages 791 - 6
OP DE BEECK ET AL., J. GEN. VIROL., vol. 82, 2001, pages 2589 - 2595
PEITSCHMANN T. ET AL.: "Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras", PROC. NATL. ACAD. SCI. USA, vol. 103, no. 19, 2006, pages 7408 - 7413, XP002461116 *
PIETSCHMANN, T. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 103, 2006, pages 7408 - 7413
PILERI ET AL., SCIENCE, vol. 282, 1998, pages 938 - 941
ROCCASECCA R. ET AL.: "Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2", J. VIROLOGY, vol. 77, no. 3, 2003, pages 1856 - 1867, XP002587676 *
SAITO ET AL., JIKKEN IGAKU, vol. 9, 1991, pages 2075 - 2080
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", vol. 3, 2001, COLD SPRING HARBOR LABORATORY
SATO, K. ET AL., CANCER RES., vol. 53, 1993, pages 851 - 856
See also references of EP2177535A4
SUZUKI ET AL., SAISHIN IGAKU, vol. 58, 2003, pages 2017 - 2022
TAKEUCHI ET AL., GASTROENTEROLOGY, vol. 116, 1999, pages 636 - 42
TAKEUCHI T. ET AL., GASTROENTEROLOGY, vol. 116, 1999, pages 636 - 642
TARR A.W. ET AL.: "Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33", HEPATOLOGY, vol. 43, no. 3, 2006, pages 592 - 601, XP002486650 *
WAKITA ET AL., J.BIOL.CHEM., vol. 269, 1994, pages 14205 - 14210
WAKITA T. E TAL.: "Production of infectious hepatitis C virus in tissue culture from a cloned viral genome", NATURE MEDICINE, vol. 11, no. 7, 2005, pages 791 - 796, XP002993378 *
WAKITA, T. ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 14205 - 14210
WAKITA, T. ET AL., NAT. MED., vol. 11, 2005, pages 791 - 796
YANAGI, M. ET AL., VIROLOGY, vol. 262, 1999, pages 250 - 263
ZHANG P. ET AL.: "Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma", PROC. NATL. ACAD. SCI. USA, vol. 104, no. 20, 15 May 2007 (2007-05-15), pages 8449 - 8454, XP002515098 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011052735A1 (ja) * 2009-10-30 2011-05-05 東レ株式会社 C型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体及びその用途
CN102596996A (zh) * 2009-10-30 2012-07-18 东丽株式会社 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
US8592559B2 (en) 2009-10-30 2013-11-26 Toray Industries, Inc. Antibody having activity of inhibiting hepatitis C virus (HCV) infection and use thereof
JP5756757B2 (ja) * 2009-10-30 2015-07-29 東レ株式会社 Ｃ型肝炎ウイルス（ｈｃｖ）に対して感染阻害活性を有する抗体及びその用途
JPWO2012133735A1 (ja) * 2011-03-31 2014-07-28 国立感染症研究所長 遺伝子型１ｂのＣ型肝炎ウイルスゲノム由来の核酸を含む核酸構築物、及び該核酸構築物が導入されたＣ型肝炎ウイルスゲノム複製細胞、並びに感染性Ｃ型肝炎ウイルス粒子の製造方法

Also Published As

Publication number Publication date
CN101809033A (zh) 2010-08-18
CA2694397A1 (en) 2009-01-29
JPWO2009014216A1 (ja) 2010-10-07
AU2008280057A1 (en) 2009-01-29
US20100291545A1 (en) 2010-11-18
EP2177535A1 (en) 2010-04-21
EP2177535A4 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
WO2009014216A1 (ja) Ｃ型肝炎ウイルス（hcv）に対して感染阻害活性を有する抗体およびその用途
HK1112481A1 (en) Modified human hepatitis c virus genomic rna having autonomous replicative competence
WO2004111082A3 (fr) Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
Kato Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation
Pavio et al. The hepatitis C virus persistence: how to evade the immune system?
GEP20104956B (en) Compounds for inhibiting hepatitis c viral replication and use thereof
WO2009039246A3 (en) Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection
WO2007140254A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
EP1930416A4 (en) NEW RECOMBINANT PARTICLE SIMILAR TO HUMAN HEPATITIS C VIRUS AND METHOD FOR THE MANUFACTURE THEREOF
WO2006131936B1 (en) Hepatitis c virus vaccine
WO2006039326A3 (en) Inhibitors of hepatitits c virus
ATE555800T1 (de) Zusammensetzung mit dem polyprotein ns3/ns4 und dem polypeptid ns5b von hcv, expressionsvektoren mit den entsprechenden nukleinsäuresequenzen und ihre therapeutische verwendung
Varshney et al. A review on an update of NS5B polymerase hepatitis C virus inhibitors
Luna et al. Taming a beast: lessons from the domestication of hepatitis C virus
WO2007031867A3 (en) A hepatitis c virus non-stru tural ns3/4a fusion gene
DK1417233T3 (da) Humant rekombinant antistof mod det hepatitis C (HCV) ikke-strukturelle NS3-protein, nukleinsyre og anvendelser deraf
Chopra Characteristics of the hepatitis C virus
Hong et al. Selection of peptides binding to HCV e2 and inhibiting viral infectivity
McGarvey et al. Restricted quasispecies variation following infection with the GB virus B
Pandya et al. Expression and purification of E2/NS1 protein of hepatitis C virus and detection of anti-E2/NS1 antibodies in chronic liver disease patients
JP2005506997A5 (ja)
Omata et al. Recent advances in hepatitis C virus research
GB0215617D0 (en) Use of hepatitis C virus (HCV) p7 protein
Fukuda et al. RNA aptamers specific for the HCV NS3 protease and helicase domains

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880108581.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08791668

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009524526

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12670383

Country of ref document: US

Ref document number: 2694397

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008280057

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008791668

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008280057

Country of ref document: AU

Date of ref document: 20080725

Kind code of ref document: A